Sterling Capital Management LLC Has $10.33 Million Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Sterling Capital Management LLC boosted its Bristol Myers Squibb stake by 442.1% in the first quarter, ending with 170,257 shares valued at about $10.33 million.
• Bristol Myers Squibb recently beat quarterly earnings expectations, reporting $1.58 EPS versus the $1.42 estimate on revenue of $11.49 billion, and it reaffirmed a full-year outlook that analysts expect to come in around $6.32 EPS.
• The company also announced a $0.63 quarterly dividend, equal to $2.52 annually and a 4.4% yield; meanwhile, Wall Street currently has a Hold consensus rating with a target price of $61.31.

Sterling Capital Management LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 442.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 170,257 shares of the biopharmaceutical company's stock after purchasing an additional 138,851 shares during the period. Sterling Capital Management LLC's holdings in Bristol Myers Squibb were worth $10,326,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BMY. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $1,947,272,000. AQR Capital Management LLC raised its stake in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock valued at $1,391,485,000 after acquiring an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock worth $1,321,308,000 after purchasing an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC boosted its position in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Finally, Man Group plc grew its holdings in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock valued at $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $57.45 on Friday. The firm's 50-day moving average is $57.06 and its 200-day moving average is $57.27. The company has a market cap of $117.31 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion during the quarter, compared to analysts' expectations of $10.93 billion. During the same quarter last year, the company earned $1.80 earnings per share. The firm's revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 70.79%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Citigroup reissued a "neutral" rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. HSBC lifted their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a "hold" rating in a report on Tuesday, March 17th. Bank of America decreased their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Cantor Fitzgerald lifted their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 8th. Finally, Guggenheim reissued a "buy" rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.